Back to results
US 12,691,090 B2Granted
Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
AssigneeXwpharma Ltd.
InventorsDaniel M. Canafax, William W. Xiang, Leonard Blum, Jia-Ning Xiang
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and γ-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.
Claims18
A pharmaceutical composition comprising:
- a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
- the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid;
- and
- the immediate release granules are uncoated or comprise an immediate release coating;
- and
- a second component comprising modified release granules, wherein the modified release granules comprise:
- a core comprising 4-((L-valyl)oxy)butanoic acid;
- and
- a modified release coating surrounding the core, wherein
- a molar ratio of 4-((L-valyl)oxy)butanoic acid in the first to 4-((L-valyl)oxy)butanoic acid in the second component is from 1:1 to 1:10.
7 more elements
A pharmaceutical composition comprising:
- a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
- the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid;
- and
- the immediate release granules are uncoated or comprise an immediate release coating;
- and
- a second component comprising modified release granules, wherein the modified release granules comprise:
- a core comprising 4-((L-valyl)oxy)butanoic acid;
- and
- a modified release coating surrounding the core, wherein
- the first component comprises from 5 mol % to 40 mol % of 4-((L-valyl)oxy)butanoic acid;
- the second component comprises from 60 mol % to 90 mol % of 4-((L-valyl)oxy)butanoic acid;
- and
- mol % is based on the total moles of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.
10 more elements
A pharmaceutical composition comprising:
- a first component, wherein the first component is selected from a solution comprising 4-((L-valyl)oxy)butanoic acid and immediate release granules, wherein
- the immediate release granules comprise 4-((L-valyl)oxy)butanoic acid;
- and
- the immediate release granules are uncoated or comprise an immediate release coating;
- and
- a second component comprising modified release granules, wherein the modified release granules comprise:
- a core comprising 4-((L-valyl)oxy)butanoic acid;
- and
- a modified release coating surrounding the core, wherein
- the first component comprises from 10 wt % to 50 wt % of 4-((L-valyl)oxy)butanoic acid, and
- the second component comprises from 50 wt % to 90 wt % of 4-((L-valyl)oxy)butanoic acid, and
- wherein wt % is based on the total weight of 4-((L-valyl)oxy)butanoic acid in the pharmaceutical composition.
9 more elements
Dependencies are inferred from the claim text.